Genetic Engineering & Biotechnology News covers Atomwise’s recent paper in Nature Scientific Reports.
In the paper published in Scientific Reports titled, “AI is a viable alternative to high throughput screening: a 318-target study,” AtomNet was applied to 318 targets identified from collaborations from over 250 academic labs across 30 countries. The platform successfully identified structurally novel hits for 235 of 318 targets evaluated, and provided a success rate of 74%, an improvement upon literature estimated HTS success rates of 50%.
“It’s important to be able to go into novel parts of chemical space because if you want to help patients, you have to be meaningfully differentiated in the clinic,” said Abraham Heifets, CEO of Atomwise, highlighting that such differentiation comes from providing first-in-class strategies when no treatment exists or improving upon existing strategies.
Read the article:
👇👇
https://lnkd.in/e9UEzscc
#AI #drugdiscovery